[1] Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 2007,450:566-569.
[2] Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol, 2007,37:3021-3029.
[3] Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family. Immunol Rev, 2008,226:248-262.
[4] Huang CH, Loo EX, Kuo IC, et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol, 2011,187:462-471.
[5] Tedder TF, Leonard WJ. Autoimmunity: regulatory B cells--IL-35 and IL-21 regulate the regulators. Nat Rev Rheumatol, 2014,10:452-453.
[6] Terayama H, Yoshimoto T, Hirai S, et al. Contribution of IL-12/IL-35 common subunit p35 to maintaining the testicular immune privilege. PLoS One, 2014,9:e96120.
[7] Hasegawa H, Mizoguchi I, Chiba Y, et al. Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family. Front Immunol, 2016,7:479.
[8] Floss DM, Schönberg M, Franke M, et al. IL-6/IL-12 cytokine receptor shuffling of extra- and intracellular domains reveals canonical STAT activation via synthetic IL-35 and IL-39 signaling. Sci Rep, 2017,7:15172.
[9] Michaud D, Mirlekar B, Steward C, et al. B cell receptor signaling and protein kinase D2 support regulatory B cell function in pancreatic cancer. Front Immunol, 2021,12:745873.
[10] Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J, 2019,16:48.
[11] Turnis ME, Sawant DV, Szymczak-Workman AL, et al. Interleukin-35 limits anti-tumor immunity. Immunity, 2016,44:316-329.
[12] Yang L, Shao X, Jia S, et al. Interleukin-35 dampens CD8(+) T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma. Front Immunol, 2019,10:1032.
[13] Cheng ST, Yuan D, Liu Y, et al. Interleukin-35 level is elevated in patients with chronic hepatitis B virus infection. International Journal of Medical Sciences, 2018,15:188-194.
[14] Teng DK, Liu Y, Lv YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol, 2019,70:252-259.
[15] Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4 + CD25 + CD127 dim/- regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virology Journal, 2019,16(1):48.
[16] Langhans B, Braunschweiger I, Arndt S, et al. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond), 2010,119:97-109.
[17] Liu S, Zhang Q, Shao X, et al. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. Int Immunopharmacol, 2017,50:87-94.
[18] Huang C, Shen Y, Shen M, et al. Glucose metabolism reprogramming of regulatory t cells in concanavalin a-induced hepatitis. Front Pharmacol, 2021,12:726128.
[19] Wang W, Guo H, Li H, et al. IL-35 gene modified mesenchymal stem cells protect the con a induced fulminant hepatitis through decreasing the IFN-g level. Human Gene Therapy, 2017,171.
[20] Li T, Huang Y, Liu P, et al. Lower plasma levels of il-35 in patients with primary biliary cirrhosis. Tohoku J Exp Med, 2018,244:123-131.
[21] Park AC, Huang G, Jankowska-Gan E, et al. Mucosal administration of collagen v ameliorates the atherosclerotic plaque burden by inducing interleukin 35-dependent tolerance. J Biol Chem, 2016,291:3359-3370.
[22] Sun HQ, Zhang JY, Zhang H, et al. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat, 2012,19:396-403.
[23] Shi M, Wei J, Dong J, et al. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis. Mol Med Rep, 2015,11:121-126.
[24] Tsuda M, Zhang W, Yang GX, et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology, 2013,57:806-816.
[25] Khamri W, Gudd C, Liu T, et al. Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis. Gut, 2022,71(6):1192-1202.
[26] Peng M, Qiang L, Xu Y, et al. IL-35 ameliorates collagen-induced arthritis by promoting TNF-α-induced apoptosis of synovial fibroblasts and stimulating M2 macrophages polarization. FEBS J, 2019,286:1972-1985.
[27] Hu S, Lian PP, Hu Y, et al. The role of il-35 in the pathophysiological processes of liver disease. Front Pharmacol, 2020,11:569575.
[28] Tsai CL, Chang JS, Yu MC, et al. Functional genomics identifies hepatitis-induced STAT3-TYRO3-STAT3 signaling as a potential therapeutic target of hepatoma. Clin Cancer Res, 2020,26:1185-1197.
[29] Liu X, Ren H, Guo H, et al. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clin Exp Immunol, 2021,203:219-229.
[30] Zhang Q, Yang L, Liu S, et al. Interleukin-35 suppresses Interleukin-9-Secreting CD4(+) T Cell Activity in patients with hepatitis B-Related hepatocellular carcinoma. Front Immunol, 2021,12:645835.
[31] He Y, Pei JH, Li XQ, et al. IL-35 promotes EMT through STAT3 activation and induces MET by promoting M2 macrophage polarization in HCC. Biochem Biophys Res Commun, 2021,559:35-41.
[32] Koda Y, Nakamoto N, Chu PS, et al. Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35. J Clin Invest, 2019,129(8):3201-3213.
[33] Yang L, Zhang Q, Song J, et al. Interleukin-35 suppresses CD8(+) T cell activity in patients with viral hepatitis-induced acute-on-chronic liver failure. Dig Dis Sci, 2020,65:3614-3623.
[34] Chen L, Sun W, Wang Y, et al. Lower levels of interleukin-35 in patients with prophase of liver failure are associated with progression to liver failure. Ann Palliat Med, 2021,10:9174-9183. |
